First, population-based cancer registration is aimed at monitoring outcomes only, and does not contain detailed clinical information on prognostic factors (hormone receptor status, HER2/neu status, histological grade, and number of lymph node metastases) or treatment modalities (hormone therapy, chemotherapy, and radiotherapy), so we were unable to conduct further factorial analyses for outcomes. Here, ERBB2 is linked to cancer.